Intelivation Technologies received FDA approval for the Advantage-C™ PEEK Cervical Interbody Fusion device

Intelivation Technologies, a medical device company with a growing product portfolio announced today that they have achieved FDA 510(k) Clearance of the Advantage-C™ PEEK Cervical Interbody Fusion device.

The Advantage-C™ Device is designed to be used in skeletally mature patients in levels C2-T1 in conjunction with fixation for ACDF (anterior cervical discectomy and fusion) procedures. Advantage-C™ was developed to optimize fusion, while maintaining elasticity that is similar to bone and radiolucency of the cage body.

President Amit Sinha stated, “I am excited about the FDA Approval of Advantage-C™ and the myriad of efficiencies this device will bring to both surgeons and hospital systems alike.”

CEO Rob Anderson added “Our growing line of interbody devices further drives home our commitment to innovating cost-effective spinal solutions that consistently provide superior clinical results, and the Management Team looks forward to a successful launch during the 36th Annual NASS Meeting in Boston September 29-Ocotber 2, 2021.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version